{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-025167","form_type":"8-K","ticker":null,"cik":"0001733413","company_name":"TFF Pharmaceuticals, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.335610+00:00","generated_at":"2026-06-04T09:08:44.367602+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TFF Pharmaceuticals raises ~$1.2M in registered direct offering with warrants at $8.00/share","bullets":["Sold 147,500 shares at $8.00 in registered direct offering; gross proceeds ~$1.2M.","Concurrent private placement of warrants to purchase 147,500 shares at $8.00; exercisable for 5.5 years.","H.C. Wainwright acted as sole placement agent; receives 7% cash fee and 10,325 warrants at $10.00.","Net proceeds to be used for working capital and general corporate purposes.","Closing occurred March 22, 2024; offering priced at-the-market under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-025167","json":"https://secwatch.observer/filing/0001213900-24-025167.json","markdown":"https://secwatch.observer/filing/0001213900-24-025167.md","text":"https://secwatch.observer/filing/0001213900-24-025167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/0001213900-24-025167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/ea0202366-8k_tffpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:08:44.367602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"145e3f7cc30785011774c3edcfd1de4bb94b7bc4","claim":"TFF Pharmaceuticals, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.","evidence_excerpt":"In connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/0001213900-24-025167-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"}],"fact_type":"material_agreement"},{"claim_id":"fd2467e744fff0b18322fe3ed678a11f218f02f8","claim":"TFF Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $1.2 million (effective 2024-03-20).","evidence_excerpt":"On March 20, 2024, TFF Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market (the “Registered Offering”), an aggregate of 147,500 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $8.00 per share (the “Shares”), for gross proceeds from the Registered Offering of approximately $1.2 million, before deducting the placement agent fee and estimated offering expenses.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024025167/0001213900-24-025167-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $1.2 million"},{"label":"Effective","value":"2024-03-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}